Você procurou por: breast fed infants (Inglês - Maltês)

the effects on breast-fed infants are unknown.
l-effetti fuq trabi li qed jieħdu l-ħalib tas-sider m'humiex magħrufin.

may cause harm to breast-fed children.
h362

the effect on breast-fed infants of administration of strimvelis to their mothers has not been studied.
ma ġiex studjat l-effett tal- għoti ta' strimvelis lill-ommijiet fuq it-trabi tagħhom li qed ireddgħu.

a risk to the breast-fed infant cannot be excluded.
ma jistax jiġi eskluż riskju għat-tarbija li tkun qed terda’.

in the absence of data in breast-fed infants, breast-feeding discontinuation is recommended after receiving cyanokit.
fl-assenza ta’ dejta fi trabi li jkunu qed jiġu mreddgħa, it-twaqqif tat-treddigħ hu rakkomandat wara li l-pazjenta tirċievi cyanokit.

the effect on breast-fed infants of the administration of this vaccine has not been assessed; no contraindication has been established.
28 ma tqiesx l- effett ta ’ l- amministrazzjoni ta ’ dan il- vaċċin fuq trabi li qed ireddgħu; ma ġiet stabbilita l - ebda kontra- indikazzjoni.

because of the potential for serious undesirable effects in breast-fed infants, lactation should be discontinued during treatment with velcade.
minħabba l- potenzjal ta 'effetti serji mhux mixtieqa fit- trabi li jitreddgħu, it- treddigħ għandu jitwaqqaf waqt kura b’ velcade.

because of the potential for adverse reactions in breast-fed infants from temsirolimus, breast-feeding should be discontinued during therapy.
minħabba l-potenzjal għal reazzjonijiet avversi minn temsirolimus fi trabi li jkunu qed jerdgħu, it-treddigħ għandu jitwaqqaf matul il-kura.

fentanyl can get into breast milk and may cause side effects in the breast-fed infant.
fentanyl jista’ jgħaddi fil-ħalib tas-sider u jista’ jikkawża effetti mhux mixtieqa fit-tarbija li qed terda.

considering the potential for serious adverse reactions due to fulvestrant in breast-fed infants, lactation is contraindicated (see section 4.3).
(ara sezzjoni 4. 3)

patients on kentera therapy should keep application sites covered with clothing when coming into contact with breast-feeding or pregnant women or breast-fed infants.
pazjenti li jkunu qegħdin fuq terapija b’kentera għandhom iżommu s-siti tal-applikazzjoni mgħottija bil- ħwejjeġ meta jiġu f’kuntatt ma’ nisa tqal jew li qegħdin ireddgħu jew ma’ trabi li jkunu qegħdin jitreddgħu.

because of the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue breast-feeding or rebif therapy.
minħabba l-potenzjal ta’ effetti serji negattivi fuq trabi li jerdgħu, deċiżjoni għandha tittieħed jekk jitwaqqafx it-treddigħ jew inkella t-terapija b’rebif.

studies have shown that breast-feeding postpartum women vaccinated with live attenuated rubella vaccines may secrete the virus in breast milk and transmit it to breast-fed infants.
studji wrew li nisa li jreddgħu wara l-ħlas u li ġew imlaqqma bil-vaċċin tal-ħosba Ġermaniża tat-tip ħaj attenwat jistgħu jerħu l-virus fil-ħalib u jitrassmettuh lit-trabi li jkunu qed irreddgħu.

because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, cellcept is contraindicated in nursing mothers (see section 4.3).
minħabba l-potenzjal ta’ effetti avversi serji għal mycophenolate mofetil fi trabi li jkunu qed jingħataw il-ħalib tas-sider, cellcept huwa kontraindikat f’nisa li qed ireddgħu (ara sezzjoni 4.3).

it is not known whether xigris is excreted in human milk or if there is a potential effect on the breast- fed infant.
mhux magħruf jekk xigris joħroġx fil-ħalib tal-bniedem jew jekk hemm xi effett potenzjali fuq it- tarbija li titradda’.

fentanyl passes into the breast-milk and may cause side effects in the breast-fed infant as sedation and respiratory depression.
fentanyl joħroġ fil- ħalib tas- sider u għaldastant jista ’ jkollu effetti sedattivi u jikkawza dipressjoni respiratorja fit- trabi li għadhom qed jerdgħu.

due to the potential harmful effects for the breast fed infant, breast-feeding should be avoided during maternal treatment with rufinamide.
minħabba l-effetti potenzjali ta’ ħsara lit-tarbija li tkun qed tiġi mredda’, it-treddigħ għandu jiġi evitat waqt il-kura tal-omm b’rufinamide.

as the potential for harm to the breast fed infant is unknown, women should not breast-feed during the period immediately following treatment with this medicine.
peress li l-potenzjal għall-ħsara għat- tarbija li hi mredda’ mhux magħruf, in-nisa m’għandhomx ireddgħu matul il-perijodu immedjatament wara t-trattament b’din il-mediċina.

because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, mycophenolate mofetil teva is contraindicated in breast-feeding mothers (see section 4.3).
minħabba fir-riskju potenzjali għar- reazzjonijiet avversi serji għal mycophenolate mofetil fi trabi li jkunu mredda’, mycophenolate mofetil teva huwa kontra-indikat f’ommijiet li jkunu qegħdin ireddgħu (ara sezzjoni 4.3).

paliperidone is excreted in the breast milk to such an extent that effects on the breast-fed infant are likely if therapeutic doses are administered to breast-feeding women.
paliperidone jiġi eliminat fil-ħalib tas-sider tant li aktarx ikun hemm effetti fuq it-trabija li qed titredda’jekk jingħataw dożi terapewtiċi lil nisa li qed ireddgħu.